The drug culture that once terrified the American right now sits at the center of a new conservative business and policy push.
That reversal comes into focus through a striking political contrast. In 1966, Senator Ted Kennedy pressed Timothy Leary in a US Senate hearing that captured the era’s alarm over LSD, hippie culture and anti-war unrest. Nearly 60 years later, reports indicate Robert F Kennedy Jr stood beside Donald Trump as he signed an executive order aimed at speeding mainstream access to psychedelic-based medical treatment. The symbolism matters: a substance once cast as a threat to social order now enters the language of treatment, investment and state-backed reform.
What changed is not just the science around psychedelics, but the politics of who gets to profit from them and who gets to call them medicine.
The new coalition did not emerge from counterculture nostalgia. It grew through veterans’ lobbying, a broader push for mental-health treatments, and Silicon Valley capital looking for the next frontier. The signal points in particular to ibogaine, a psychoactive compound derived from a West African shrub, which scientists suggest may help address chronic mental-health problems. Figures such as Kennedy Jr and Joe Rogan have helped carry that case into conservative circles, reframing psychedelics less as rebellion than as therapy, recovery and market opportunity.
Key Facts
- US conservatives once treated psychedelics as symbols of social breakdown and political disorder.
- Reports indicate Donald Trump signed an executive order to accelerate access to psychedelic-based medical treatment.
- Robert F Kennedy Jr has emerged as a prominent advocate for psychedelics within the Maga coalition.
- Ibogaine has drawn attention as a potential treatment for chronic mental-health problems, according to scientists cited in reports.
The shift also exposes a deeper truth about drug politics in America. Public attitudes rarely move on science alone; they move when power, money and cultural legitimacy line up. Psychedelics have traveled from the margins to the mainstream not because their history disappeared, but because new champions now frame them in terms the right can sell: healing for veterans, personal optimization, deregulation and commercial scale. That makes this more than a health story. It is a story about who shapes the future of medicine and who stands to win from it.
What happens next will likely hinge on regulation, clinical evidence and the speed at which political enthusiasm turns into durable policy. If the current push holds, psychedelics could move faster into American medicine and business than many expected. That matters because the debate no longer asks whether these drugs belong only to the counterculture. It asks who will control their mainstream future — and who will cash out when they do.